Facinicline

Facinicline (development code RG3487) is a α7 nicotinic acetylcholine receptor partial agonist and antagonist to serotonin-3 receptors (5-HT₃). It demonstrated initial efficacy for treating cognitive impairment in Alzheimer's disease in a phase 2a trial, but development was discontinued following the conclusion of a later phase 2 trial.^[1]

Quick facts Names, Identifiers ...

Facinicline

Names
IUPAC name N-[(3S)-1-Azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide
Other names RG3487
Identifiers
CAS Number	677306-35-3 HCl: 677305-02-1
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL2151439 HCl: ChEMBL5095032
ChemSpider	8145949 HCl: 8555915
PubChem CID	9970357 HCl: 10380472
UNII	6A6FX0J03K HCl: O6J463N18M
InChI InChI=1S/C15H18N4O/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18)/t13-/m1/s1 Key: TXCYUSKWBHUVEP-CYBMUJFWSA-N
SMILES C1CN2CCC1[C@@H](C2)NC(=O)C3=NNC4=CC=CC=C43
Properties
Chemical formula	C15H18N4O
Molar mass	270.336 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Close

A later study evaluating the effects of facinicline on cognitive deficits in schizophrenia failed to demonstrate an effect on its primary endpoints, although post-hoc analysis showed improvements in patients with high negative PANSS scores.^[1][2]